Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5782184 | 0.88 | RAB9A (0.39) | RAB9ANPC1MAPTGAASMN1; SMN2 | |
| SCHEMBL2009205 | 0.85 | SMN1; SMN2 (0.51) | RAB9ANPC1MAPTSMN1; SMN2CA12 | |
| SCHEMBL2013987 | 0.79 | MAPT (0.49) | RAB9ANPC1MAPTSMN1; SMN2CA12 | |
| Methenamine SCHEMBL5801339 | 0.79 | EPHX2 (0.48) | RAB9ANPC1MAPTSMN1; SMN2CA12 | |
| SCHEMBL16215508 | 0.78 | ALDH1A1 (0.55) | RAB9ANPC1MAPTGAACA12 | |
| SCHEMBL2014794 | 0.77 | L3MBTL1 (0.40) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL8377749 | 0.77 | CA12 (0.44) | RAB9ANPC1MAPTSMN1; SMN2CA12 | |
| SCHEMBL882755 | 0.76 | HDAC1 (0.44) | MAPTSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL1295592 | 0.76 | PLA2G4B (0.50) | RAB9ANPC1MAPTSMN1; SMN2CA12 | |
| SCHEMBL19331720 | 0.76 | CA1 (0.49) | RAB9ANPC1MAPTSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | RAB9A 2816/4885NPC1 4226/4885MAPT 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.